Wednesday, 14 October 2026European Markets

KAUFMAN ET BROAD And KID Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - kaufman et broad (kof.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
kaufman et broad (kof.pa) €27.00 7.15% 25.33%
kid (kid.ol) kr153.00 6.16% 29.84%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. kaufman et broad (kof.pa)

7.15% forward dividend yield and 25.33% return on equity

kaufman & broad s.a. operates as a property developer and builder in france. it designs, develops, builds, and sells single-family homes in communities, managed residences, offices, shops, hotels, and logistics platforms and business parks. the company was founded in 1968 and is headquartered in courbevoie, france.

earnings per share

as for profitability, kaufman et broad has a trailing twelve months eps of €3.1.

pe ratio

kaufman et broad has a trailing twelve months price to earnings ratio of 8.71. meaning, the purchaser of the share is investing €8.71 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.33%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, kaufman et broad's stock is considered to be oversold (<=20).

moving average

kaufman et broad's value is way under its 50-day moving average of €31.45 and below its 200-day moving average of €29.84.

volatility

kaufman et broad's last week, last month's, and last quarter's current intraday variation average was a negative 0.04%, a positive 0.33%, and a positive 1.78%.

kaufman et broad's highest amplitude of average volatility was 0.79% (last week), 1.98% (last month), and 1.78% (last quarter).

volume

today's last reported volume for kaufman et broad is 11891 which is 11.31% below its average volume of 13408.

more news about kaufman et broad.

2. kid (kid.ol)

6.16% forward dividend yield and 29.84% return on equity

kid asa, together with its subsidiaries, operates as a home textile retailer in norway, sweden, finland, and estonia. it designs, sources, markets, and sells a range of home and interior products, including textiles, curtains, bed linens, home accessories, decorations, furniture, and other interior products through retail stores and online platforms. the company provides its products under the kid, hemtex, dekosol, nordun, and premium collection brands. it also offers logistics services. the company was formerly known as nordisk tekstil holding as and changed its name to kid asa. kid asa was founded in 1937 and is headquartered in lier, norway.

earnings per share

as for profitability, kid has a trailing twelve months eps of kr8.94.

pe ratio

kid has a trailing twelve months price to earnings ratio of 17.11. meaning, the purchaser of the share is investing kr17.11 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.84%.

more news about kid.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com